allogeneic adipose-derived stem cells (GXCPC1) / GWO XI Stem Cell Applied Tech - LARVOL DELTA

Safety and Tolerability of Intra-Articular Injection of Adipose-Derived Mesenchymal Stem Cells GXCPC1 in 11 Subjects With Knee Osteoarthritis: A Nonrandomized Pilot Study Without a Control Arm. (PubMed, Cell Transplant) - "Although this study included a limited number of subjects without a placebo arm, it showed that the intra-articular injection of ADSCs was safe and well-tolerated in subjects with therapeutic alternatives to treat knee OA. However, a larger scale study with an appropriate control would be necessary for clinical efficacy in the following study."

Journal • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (GXCPC1) for Knee Osteoarthritis (clinicaltrials.gov) - P1/2 | N=25 | Completed | Sponsor: Gwo Xi Stem Cell Applied Technology Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Oct 2023 ➔ Mar 2023

Trial completion • Trial completion date • Immunology • Osteoarthritis • Pain • Rheumatology

Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (GXCPC1) for Knee Osteoarthritis (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Gwo Xi Stem Cell Applied Technology Co., Ltd. | Trial completion date: Oct 2022 ➔ Oct 2023 | Trial primary completion date: Dec 2021 ➔ Oct 2023

Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (GXCPC1) for Knee Osteoarthritis (clinicaltrials.gov) - P1/2; N=30; Recruiting; Sponsor: Gwo Xi Stem Cell Applied Technology Co., Ltd.; Phase classification: P2 ➔ P1/2

Phase classification • MRI

A Dose- Escalation Phase I Study to Evaluate Safety and Phase II Study to Evaluate Efficacy of GXCPC1 to Osteoarthritis (clinicaltrials.gov) - P2; N=30; Recruiting; Sponsor: Gwo Xi Stem Cell Applied Technology Co., Ltd.; Not yet recruiting ➔ Recruiting; Trial completion date: Mar 2022 ➔ Oct 2022

Clinical • Enrollment open • Trial completion date • MRI

A Dose- Escalation Phase I Study to Evaluate Safety and Phase II Study to Evaluate Efficacy of GXCPC1 to Osteoarthritis (clinicaltrials.gov) - P2; N=24; Not yet recruiting; Sponsor: Gwo Xi Stem Cell Applied Technology Co., Ltd.; Initiation date: Jul 2019 ➔ Nov 2019

Clinical • Trial initiation date